We aimed to produce a multidisciplinary consensus statement on behalf of the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists and the Society for Obesity and Bariatric Anaesthesia for the elective peri‐operative management of adults taking GLP‐1RAs or SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.